Product Description
IRX-2 is a primary cell-derived biologic that reduces the immune suppression that is often seen in the cancer tumor micro-environment, restores immune function and activates a coordinated immune response against the tumor. IRX-2 is a complex proprietary therapeutic containing numerous active cytokine components, which restores and activates multiple immune cell types including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00210470)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Unknown
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Brooklyn ImmunoTherapeutics
Company Location: BROOKLYN NY 11220
Company CEO: Matthew Angel
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Squamous Cell Carcinoma|Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Carcinoma in Situ|Head and Neck Cancer|Cervical Cancer
Phase 1: Head and Neck Cancer|Squamous Cell Carcinoma|Papilloma|Hepatocellular Carcinoma|Oropharyngeal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03655002 |
NCI-2018-01786 | P1 |
Active, not recruiting |
Hepatocellular Carcinoma |
2026-03-30 |
2025-06-18 |
||
NCT03575234 |
IRB00102105 | P1 |
Withdrawn |
Squamous Cell Carcinoma|Oropharyngeal Cancer|Papilloma |
2026-01-31 |
50% |
2019-08-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03381183 |
MCC-19356 | P1 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2022-05-12 |
50% |
2025-05-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT03267680 |
VIN 3 | P2 |
Terminated |
Cervical Cancer|Carcinoma in Situ|Squamous Cell Carcinoma |
2023-08-04 |
2% |
2025-04-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2016-000373-21 |
2016-000373-21 | P2 |
Terminated |
Squamous Cell Carcinoma |
2023-03-30 |
2025-07-01 |
Treatments |
|
NCT03918499 |
NCI-2018-01885 | P2 |
Completed |
Adenocarcinoma|Gastrointestinal Cancer|Esophageal Cancer |
2023-02-09 |
2023-03-24 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT02609386 |
INSPIRE | P2 |
Completed |
Squamous Cell Carcinoma |
2022-02-28 |
12% |
2024-01-31 |
Primary Endpoints|Start Date|Treatments |
NCT00210470 |
IRX-2 2005-A | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2010-12-01 |
2020-12-12 |
Primary Endpoints|Study Completion Date|Treatments |